BIOXYTRAN, INC
BIXT · OTCMCIK 1445815fmd_0EFSQSZMD63J1H5GF9ATPGCZZ5Manufacturing · Pharmaceutical PreparationsTemplate: Standard
Coverage: Jan 01, 2009 to Jun 30, 2026, 66 periods
| Line item | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Total revenues | 0 | 0 | – | – | – | – | – | – | – | – |
| Cost of revenue | 0 | 0 | – | – | – | – | – | – | – | – |
| Gross profit | 0 | 0 | – | – | – | – | – | – | – | – |
| Research and development | – | – | – | – | 1 | 2 | 1 | 1 | 0 | 0 |
| Selling, general and administrative | 1 | 0 | – | – | – | – | – | – | – | – |
| Total operating expenses | 1 | 0 | 0 | 2 | 1 | 4 | 2 | 4 | 2 | 2 |
| Operating income | (1) | (0) | (0) | (2) | (1) | (4) | (2) | (4) | (2) | (2) |
| Interest expense | 0 | 0 | 0 | 0 | 1 | 2 | – | 0 | 0 | 0 |
| Interest and investment income | – | – | – | – | – | – | – | – | – | – |
| Other non-operating income (expense) | (0) | (0) | (0) | (0) | (1) | (0) | (0) | (1) | (0) | (0) |
| Income before taxes | (1) | – | (0) | (2) | (3) | (5) | (3) | (5) | (2) | (2) |
| Income tax expense | – | – | 0 | – | – | – | – | – | – | – |
| Net income from continuing operations | – | – | (0) | – | – | – | – | – | – | – |
| Net income | (1) | (0) | (0) | (2) | (3) | (4) | (2) | (4) | (2) | (2) |
| Net income to common shareholders | – | – | – | – | (2) | (4) | – | – | – | – |